Physician profile
James George
NPI 1659380244
$375,751.17
in general payments reported to CMS, 2019-2025
44 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $15K · 2021: $30K · 2022: $34K · 2023: $32K · 2024: $53K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Food and Beverage: $23K · Travel and Lodging: $21K · Consulting Fee: $8,363 · Education: $93.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $172,746.86 |
| Food and Beverage | $23,452.79 |
| Travel and Lodging | $20,744.83 |
| Consulting Fee | $8,362.50 |
| Education | $93.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $145,883.69 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $88,657.19 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $86,859.88 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37,498.72 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,080.08 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $3,020.74 | 2021-2024 | Zeposia |
| Pfizer INC. | $2,793.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $894.84 | 2019-2024 | Dificid |
| Qol Medical, LLC | $875.43 | 2019-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $711.77 | 2019-2023 | Rebyota, Clenpiq |
| Amgen INC. | $690.14 | 2020-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $592.49 | 2023-2025 | Omvoh |
| Ucb, INC. | $560.82 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $373.63 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $274.31 | 2021-2024 | Injectafer |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$139,895.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.